NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.44
  • Forecasted Upside: 30.48 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$21.80
▲ +1.86 (9.33%)

This chart shows the closing price for RYTM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rhythm Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RYTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RYTM

Analyst Price Target is $28.44
▲ +30.48% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $28.44, with a high forecast of $37.00 and a low forecast of $16.00. The average price target represents a 30.48% upside from the last price of $21.80.

This chart shows the closing price for RYTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Rhythm Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$28.00Low
8/5/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$8.00 ➝ $20.00Low
8/3/2022Morgan StanleyBoost Price TargetEqual Weight$8.00 ➝ $16.00Low
8/2/2022Wells Fargo & CompanyBoost Price Target$22.00 ➝ $35.00Low
7/20/2022Stifel NicolausBoost Price Target$25.00 ➝ $37.00Low
7/15/2022Morgan StanleyBoost Price TargetEqual Weight$4.00 ➝ $8.00Low
7/13/2022LADENBURG THALM/SH SHBoost Price Target$15.00 ➝ $23.00Low
7/12/2022The Goldman Sachs GroupBoost Price TargetNeutral$4.00 ➝ $6.00Low
6/17/2022Needham & Company LLCLower Price TargetBuy$40.00 ➝ $25.00High
6/17/2022Stifel NicolausBoost Price Target$23.00 ➝ $25.00High
6/7/2022Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $4.00High
5/24/2022The Goldman Sachs GroupLower Price TargetNeutral$8.00 ➝ $7.00Low
4/7/2022The Goldman Sachs GroupLower Price TargetNeutral$10.00 ➝ $9.00High
3/7/2022Canaccord Genuity GroupLower Price Target$45.00 ➝ $36.00Low
3/7/2022Canaccord Genuity GroupLower Price TargetBuy$45.00 ➝ $36.00High
3/2/2022Stifel NicolausInitiated CoverageBuyHigh
2/25/2022Needham & Company LLCLower Price TargetBuy$50.00 ➝ $45.00Low
2/17/2022Needham & Company LLCReiterated RatingBuy$50.00High
2/17/2022LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$15.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$30.00Medium
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$50.00 ➝ $15.00High
9/14/2021The Goldman Sachs GroupUpgradeHold$14.00High
8/4/2021Morgan StanleyLower Price TargetOverweight$57.00 ➝ $54.00High
8/4/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
8/4/2021Bank of AmericaDowngradeNeutral ➝ Underperform$33.00 ➝ $17.00High
2/25/2021Morgan StanleyBoost Price TargetOverweight$53.00 ➝ $57.00Low
2/18/2021Morgan StanleyBoost Price TargetPositive ➝ Overweight$33.00 ➝ $53.00High
1/27/2021Stifel NicolausBoost Price TargetPositive ➝ Buy$36.00 ➝ $67.00Low
1/27/2021LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$43.00 ➝ $60.00High
1/5/2021Stifel NicolausReiterated RatingTop PickN/A
11/30/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $33.00Medium
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$27.00 ➝ $33.00High
11/3/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00High
10/26/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$31.00 ➝ $36.00High
8/3/2020Needham & Company LLCInitiated CoverageBuy$42.00High
8/3/2020Stifel NicolausReiterated RatingBuy$31.00High
7/16/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
6/24/2020Needham & Company LLCInitiated CoverageBuy$42.00Medium
5/4/2020Stifel NicolausReiterated RatingBuy$31.00Low
5/4/2020Needham & Company LLCReiterated RatingBuy$42.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$33.00 ➝ $31.00Low
3/31/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00High
3/2/2020Stifel NicolausReiterated RatingBuy$34.00High
1/8/2020The Goldman Sachs GroupInitiated CoverageSell$18.00High
9/25/2019CowenReiterated RatingBuy$40.00High
9/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
7/30/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00High
7/29/2019Stifel NicolausReiterated RatingBuy$34.00High
7/12/2019Stifel NicolausUpgradeHold ➝ Buy$34.00High
5/5/2019Needham & Company LLCReiterated RatingBuy$42.00Low
5/3/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
3/28/2019Stifel NicolausSet Price TargetHold$34.00High
3/13/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$43.00Low
3/8/2019CowenReiterated RatingBuy$40.00Low
12/14/2018Needham & Company LLCSet Price TargetBuy$42.00Low
12/13/2018Stifel NicolausReiterated RatingHoldLow
11/11/2018Stifel NicolausReiterated RatingHold$36.00High
9/14/2018Stifel NicolausInitiated CoverageHold$36.00High
9/7/2018Morgan StanleyInitiated CoverageOverweightLow
9/7/2018Morgan StanleySet Price TargetOverweight ➝ Buy$38.00Medium
8/9/2018Needham & Company LLCSet Price TargetBuy$42.00Medium
6/25/2018Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $42.00Low
6/15/2018Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $36.00Low
2/26/2018Needham & Company LLCReiterated RatingBuy$32.00High
11/14/2017CowenReiterated RatingBuy$40.00N/A
11/14/2017Needham & Company LLCReiterated RatingBuy$32.00N/A
10/30/2017Morgan StanleyInitiated CoverageEqual Weight$23.00N/A
10/30/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$32.00N/A
10/30/2017Bank of AmericaInitiated CoverageBuy$30.00N/A
10/30/2017CowenInitiated CoverageOutperform$40.00N/A
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/13/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/13/2022
  • 10 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
7/13/2022
  • 7 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 7 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $21.80
Low: $19.88
High: $22.89

50 Day Range

MA: $8.76
Low: $3.17
High: $22.65

52 Week Range

Now: $21.80
Low: $3.04
High: $24.44

Volume

1,304,174 shs

Average Volume

1,300,080 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Rhythm Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Rhythm Pharmaceuticals in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., LADENBURG THALM/SH SH, Morgan Stanley, Needham & Company LLC, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for RYTM.

What is the current price target for Rhythm Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Rhythm Pharmaceuticals in the last year. Their average twelve-month price target is $28.44, suggesting a possible upside of 30.5%. Stifel Nicolaus has the highest price target set, predicting RYTM will reach $37.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $16.00 for Rhythm Pharmaceuticals in the next year.
View the latest price targets for RYTM.

What is the current consensus analyst rating for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RYTM will outperform the market and that investors should add to their positions of Rhythm Pharmaceuticals.
View the latest ratings for RYTM.

What other companies compete with Rhythm Pharmaceuticals?

How do I contact Rhythm Pharmaceuticals' investor relations team?

Rhythm Pharmaceuticals' physical mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company's listed phone number is (857) 264-4280 and its investor relations email address is [email protected] The official website for Rhythm Pharmaceuticals is www.rhythmtx.com. Learn More about contacing Rhythm Pharmaceuticals investor relations.